-
公开(公告)号:US10144734B2
公开(公告)日:2018-12-04
申请号:US15858929
申请日:2017-12-29
Applicant: Array BioPharma, Inc.
Inventor: Steven W. Andrews , Sean Aronow , James F. Blake , Barbara J. Brandhuber , James Collier , Adam Cook , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L. McKenney , Oren T. McNulty , Andrew T. Metcalf , David A. Moreno , Ginelle A. Ramann , Tony P. Tang , Li Ren , Shane M. Walls
IPC: C07D471/04 , A61K31/4162 , A61P1/00 , A61P35/00
Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
-
公开(公告)号:US10137124B2
公开(公告)日:2018-11-27
申请号:US15860852
申请日:2018-01-03
Applicant: Array BioPharma, Inc.
Inventor: Steven W. Andrews , Sean Aronow , James F. Blake , Barbara J. Brandhuber , Adam Cook , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L. McKenney , Oren T. McNulty , Andrew T. Metcalf , David A. Moreno , Tony P. Tang , Li Ren
IPC: A61K31/437 , A61K31/496 , C07D471/04 , A61P1/12 , A61P35/04 , C07D519/00 , A61P35/02 , A61P35/00 , A61K31/444 , A61K31/4985 , A61K31/4995 , A61K31/506 , A61K31/5377 , A61K45/06 , A61K31/551
Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
-
公开(公告)号:US20180133200A1
公开(公告)日:2018-05-17
申请号:US15860852
申请日:2018-01-03
Applicant: Array BioPharma, Inc.
Inventor: Steven W. Andrews , Sean Aronow , James F. Blake , Barbara J. Brandhuber , Adam Cook , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L. McKenney , Oren T. McNulty , Andrew T. Metcalf , David A. Moreno , Tony P. Tang , Li Ren
IPC: A61K31/444 , A61K31/496 , A61P35/00 , A61P35/02 , A61K45/06 , A61K31/5377 , A61K31/4985 , A61K31/506 , A61K31/551
CPC classification number: C07D471/04 , A61K31/444 , A61K31/496 , A61K31/4985 , A61K31/4995 , A61K31/506 , A61K31/5377 , A61K31/551 , A61K45/06 , A61P1/12 , A61P35/00 , A61P35/02 , A61P35/04 , C07D519/00
Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
-
公开(公告)号:US20160304519A1
公开(公告)日:2016-10-20
申请号:US15197445
申请日:2016-06-29
Applicant: Array BioPharma Inc. , Genentech, Inc.
Inventor: James F. Blake , Adam Cook , John Gaudino , Indrani W. Gunawardana , Erik James Hicken , Kevin W. Hunt , Michael Lyon , Andrew T. Metcalf , Peter J. Mohr , David A. Moreno , Brad Newhouse , Li Ren , Jacob Schwarz , Huifen Chen , Lewis Gazzard , Jane Schmidt , Steve Do
IPC: C07D471/04 , A61K31/5377 , A61K31/55 , A61K31/444 , C07D487/04 , C07D519/00 , A61K45/06 , A61K31/506
CPC classification number: C07D471/04 , A61K31/444 , A61K31/506 , A61K31/5377 , A61K31/55 , A61K45/06 , C07D487/04 , C07D519/00
Abstract: Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such diseases, or associated pathological conditions are disclosed.
Abstract translation: 提供式I化合物或其立体异构体,互变异构体或其药学上可接受的盐,其可用于治疗疾病。 公开了使用式I化合物或其立体异构体,互变异构体或其药学上可接受的盐在体外,原位和体内诊断,预防或治疗这些疾病或相关病理状况的方法。
-
公开(公告)号:US20160122316A1
公开(公告)日:2016-05-05
申请号:US14993985
申请日:2016-01-12
Applicant: ARRAY BIOPHARMA INC. , GENENTECH, INC.
Inventor: James F. Blake , Mark Joseph Chicarelli , Rustam Ferdinand Garrey , John Gaudino , Jonas Grina , David A. Moreno , Peter J. Mohr , Li Ren , Jacob Schwarz , Huifen Chen , Kirk Robarge , Aihe Zhou
IPC: C07D401/04 , C07D409/14 , C07D413/14 , C07D405/14 , C07D401/14
CPC classification number: C07D401/04 , A61K31/444 , A61K31/506 , A61K31/513 , A61K31/53 , A61K45/06 , C07D401/14 , C07D403/04 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07F9/65586
Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
-
公开(公告)号:US11807651B2
公开(公告)日:2023-11-07
申请号:US17401892
申请日:2021-08-13
Applicant: Loxo Oncology, Inc. , Array BioPharma Inc.
Inventor: Charles Todd Eary , Stacey Spencer , Zack Crane , Katelyn Chando , Sylvie Asselin , Weidong Liu , Mike Welch , Adam Cook , Gabrielle R. Kolakowski , Andrew T. Metcalf , David A. Moreno , Tony P. Tang
IPC: C07D519/00 , C07D471/04
CPC classification number: C07D519/00 , C07D471/04
Abstract: In some embodiments, provided herein is a process for preparing a compound of Formula I
or a pharmaceutically acceptable salt thereof, as disclosed herein.-
公开(公告)号:US11098064B2
公开(公告)日:2021-08-24
申请号:US16902424
申请日:2020-06-16
Applicant: Loxo Oncology, Inc. , Array BioPharma Inc.
Inventor: Charles Todd Eary , Stacey Spencer , Zack Crane , Katelyn Chando , Sylvie Asselin , Weidong Liu , Mike Welch , Adam Cook , Gabrielle R. Kolakowski , Andrew T. Metcalf , David A. Moreno , Tony P. Tang
IPC: C07D519/00 , C07D471/04
Abstract: In some embodiments, provided herein is a process for preparing a compound of Formula I or a pharmaceutically acceptable salt thereof, as disclosed herein.
-
公开(公告)号:US20180133207A1
公开(公告)日:2018-05-17
申请号:US15860894
申请日:2018-01-03
Applicant: Array BioPharma, Inc.
Inventor: Steven W. Andrews , Sean Aronow , James F. Blake , Barbara J. Brandhuber , James Collier , Adam Cook , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L. McKenney , Oren T. McNulty , Andrew T. Metcalf , David A. Moreno , Ginelle A. Ramann , Tony P. Tang , Li Ren , Shane M. Walls
IPC: A61K31/4545 , A61K45/06 , A61P35/00 , A61P35/02 , A61K31/444 , A61K31/506 , A61K31/501 , A61K31/497 , A61K31/5377
CPC classification number: A61K31/4545 , A61K31/4162 , A61K31/444 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K45/06 , A61P1/00 , A61P1/12 , A61P35/00 , A61P35/02 , C07D471/04
Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
-
公开(公告)号:US20180127393A1
公开(公告)日:2018-05-10
申请号:US15625297
申请日:2017-06-16
Applicant: Array BioPharma Inc. , Genentech, Inc.
Inventor: James F. Blake , Mark Joseph Chicarelli , Rustam Ferdinand Garrey , John Gaudino , Jonas Grina , David A. Moreno , Peter J. Mohr , Li Ren , Jacob Schwarz , Huifen Chen , Kirk Robarge , Aihe Zhou
IPC: C07D401/04 , C07D471/04 , C07D417/14 , C07D409/14 , C07D413/14 , C07D405/14
Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
-
公开(公告)号:US09708290B2
公开(公告)日:2017-07-18
申请号:US14993985
申请日:2016-01-12
Applicant: ARRAY BIOPHARMA INC. , GENENTECH, INC.
Inventor: James F. Blake , Mark Joseph Chicarelli , Rustam Ferdinand Garrey , John Gaudino , Jonas Grina , David A. Moreno , Peter J. Mohr , Li Ren , Jacob Schwarz , Huifen Chen , Kirk Robarge , Aihe Zhou
IPC: A61K31/53 , C07D401/04 , C07D401/14 , C07D405/14 , C07D413/14 , C07D409/14 , C07D417/14 , C07D471/04 , A61K31/506 , A61K45/06 , C07F9/6558 , C07D403/04 , A61K31/513 , A61K31/444
CPC classification number: C07D401/04 , A61K31/444 , A61K31/506 , A61K31/513 , A61K31/53 , A61K45/06 , C07D401/14 , C07D403/04 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07F9/65586
Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
-
-
-
-
-
-
-
-
-